XOMA - NASDAQ
XOMA Royalty Corp.
$41.92
+0.55%XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotXOMA Royalty Corp. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
XOMA Royalty Corp. Income Statement
XOMA • NASDAQ
| XOMA Royalty Corp. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
52.1M | 28.5M | 4.8M | 6M | 38.2M | 29.4M | 18.4M | 5.3M | 52.7M | 5.6M | 55.4M | 18.9M | 35.5M | 33.8M | 58.2M | 33.6M | 98.4M | 68M | 84.3M | 29.5M | |
GROSS PROFIT | ||||||||||||||||||||
(3M) | (206K) | (143K) | (274K) | (171K) | (170K) | (1.3M) | (1.7M) | (7.9M) | (1.4M) | (20.7M) | (29.5M) | (27.4M) | (143K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
49.2M | 28.3M | 4.6M | 5.8M | 38M | 29.2M | 17.1M | 3.6M | 44.8M | 4.2M | 34.7M | -10.6M | 8.1M | 33.6M | 58.2M | 33.6M | 98.4M | 68M | 84.3M | 29.5M | |
OPERATING INCOME | ||||||||||||||||||||
(37.8M) | (68.3M) | (46.5M) | (23.2M) | (20.5M) | (16.8M) | (22.3M) | (20.2M) | (32.2M) | (62.6M) | (91.5M) | (100.6M) | (93.3M) | (85.2M) | (92.2M) | (100.7M) | (81.9M) | (106.7M) | (86.8M) | (70.2M) | |
(36.1M) | (34.5M) | (27.2M) | (23.2M) | (20.5M) | (16.8M) | (21M) | (18.6M) | (24.3M) | (18.3M) | (20.6M) | (19.9M) | (18.5M) | (16.9M) | (24M) | (23.3M) | (23.7M) | (24.1M) | (20.6M) | (18.1M) | |
(1.7M) | (2.9M) | (143K) | (153K) | (171K) | (170K) | (1.3M) | (1.7M) | (7.9M) | (44.2M) | (70.9M) | (80.7M) | (74.9M) | (68.3M) | (68.1M) | (77.4M) | (58.1M) | (82.6M) | (66.2M) | (52.1M) | |
11.4M | -40M | -41.8M | -17.4M | 17.5M | 12.4M | -3.9M | -16.9M | 17M | -61.6M | -39.7M | -81.8M | -58.2M | -56.6M | -34M | -67.1M | 13M | -38.7M | -2.5M | -40.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(13M) | (13.8M) | (569K) | (0.0) | (461K) | (1.8M) | (1.9M) | (922K) | (1.2M) | (3.9M) | (4.2M) | (4.3M) | (4.6M) | (4.3M) | (2.5M) | (385K) | (4.9M) | (7M) | (0.0) | (12.9M) | |
-9.6M | -13.8M | -569K | 694K | -461K | -1.8M | -1.9M | -922K | -1.2M | -3.9M | -3.8M | -4.3M | -4.6M | -4.4M | -2.5M | -385K | -4.8M | -6.1M | 0.0 | -11.3M | |
(0.0) | (30.9M) | (19.1M) | -177K | -171K | -170K | (0.0) | (4.3M) | (1.1M) | (1.5M) | (44K) | -31K | -197K | (0.0) | (0.0) | (82K) | (0.0) | (0.0) | (0.0) | (0.0) | |
20.4M | 20.5M | 1M | 295K | -1.6M | -619K | 1.9M | 3.4M | -773K | 8M | 19.1M | 43.5M | -65.9M | -14.5M | 1.2M | -1.6M | -6.7M | -6.9M | -9.8M | -11.2M | |
31.8M | -19.5M | -40.8M | -17.1M | 15.9M | 11.8M | -2M | -13.4M | 16.3M | -53.5M | -20.6M | -38.3M | -124.1M | -71.1M | -32.7M | -68.7M | 6.3M | -45.6M | -12.3M | -51.8M | |
NET INCOME | ||||||||||||||||||||
(103K) | -5.7M | (0.0) | -15K | (91K) | -1.5M | (5.7M) | -98K | (1.7M) | (0.0) | (0.0) | (0.0) | -14K | -74K | (15K) | (27K) | (5.7M) | -383K | (0.0) | (0.0) | |
31.7M | -13.8M | -40.8M | -17.1M | 15.8M | 13.3M | -2M | -13.3M | 14.6M | -53.5M | -20.6M | -38.3M | -124.1M | -71.1M | -32.7M | -68.8M | 550K | -45.2M | -12.3M | -51.8M |
SEC Filings
XOMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 16, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 27, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 30, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | February 02, 2026 | November 21, 2025 | 2025 |
Related Guides
Continue your XOMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.